Page 45 - Latest Updates on Covid-19

Study in hamsters shows convalescent plasma limits Covid-19 spread in lungs

According to the research, the lung injuries seen in the hamsters include lesions in X-ray scans called "ground glass opacities" which are also reported in human Covid-19 patients.

Fortis Malar, Lal Path Labs: Diagnostic and healthcare stocks on the charts

Stocks of diagnostic chains and hospitals have been in focus as Covid-19 pandemic spread across the country. Is it a good strategy to stay put in these counters? Here's what the charts suggest

Asian Paints rallies 7% post March quarter results; stock top Sensex gainer

For the quarter under review, the paint company posted a profit before tax (PBT) of Rs 699 crore on a consolidated basis, down 5.68 per cent year-on-year (YoY).

Patanjali announces Covid-19 medicine; govt frowns and asks for details

Patanjali has also been asked for details of the sample size, sites and hospitals where the research study was conducted

Cipla to price Covid-19 drug remdesivir at less than Rs 5,000 per vial

Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose

Farmers tap into agritech start-ups to overcome pandemic-induced woes

Apart from helping the cultivator sell his produce at a time when the markets are under lockdown, these start-ups are also using AI and IoT to help him get better yields and employ efficient sowing te

UP becomes first state to use railway isolation coaches for Covid-19

The coaches are laced with basic amenities that a patient would require -- handheld showers, mosquito nets, bio-toilets, power sockets, oxygen cylinders and more

Amway bullish on digital; sees online sales staying at 80-85% post-Covid

The company's online business which was at 33% in February hit 90% during the lockdown

Covid-19 pandemic: Abbott to supply over 1 million antibody tests to India

Abbott said it is already in the process of delivering antibody tests to leading government and private hospitals and labs across different states

Glenmark Pharma zooms 28% on launch of Favipiravir, a potential Covid drug

The company launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.

Coronavirus India dispatch: Trajectory of cases is a cause for concern

How India's invisible workforce is left to fend for itself, more than 2,000 healthcare workers have contracted Covid-19 -roundup of news on how India is dealing with the pandemic

World Coronavirus Dispatch: Saudi Arabia to resume commercial activities

Millions of European jobs at risk, Spain to accept British tourists from today, Mainland China reports 26 news cases, and other pandemic related news from across the globe

No consensus at SDMA meeting in Delhi, another scheduled for 5 pm: Sisodia

The deputy chief minister said that Delhi chief minister Arvind Kejriwal had also raised the point that if home isolation is stopped, as per the order by the LG, then problems will ensue

India does not test healthcare workers regularly, risking them & patients

India's Ministry of Health and Family Welfare (MOHFW) on May 15 had said that there was no need to quarantine healthcare workers unless they had been exposed to Covid-19

Glenmark Pharma gets nod for favipiravir; Cipla, Hetero for remdesivir

Glenmark gets nod for oral favipiravir, Maha health minister says Cipla and Hetero get nod for remdesivir

Glenmark Pharma gets nod to launch favipiravir for Covid-19 patients

Glenmark is conducting phase-3 clinical trials; drug has got restricted emergency use

IIT Guwahati develops affordable, diagnostic kits for testing Covid-19

The VTM kits are the first-stop source used to collect nasal and oral swab specimens from an individual source to a laboratory safely for culture and testing

Covid-19 impact: 1 in 5 Mumbai, Bengaluru consumers anxious about finances

The findings are based on a survey of 1,000 residents in Mumbai and Bangalore by the Swiss Re Group, a global reinsurer

Economists raise doubts over timing of economic revival after Covid-19

State Bank of India's chief economic advisor Soumya Kanti Ghosh said GDP for one quarter had been lost, amounting to Rs 40-50 trillion, due to the coronavirus crisis

NITI Aayog recommends lower rates for isolation beds in Delhi hospitals

The committee has recommended Rs 8,000-10,000, 13,000-15,000 and 15,000-18,000, including PPE costs, for isolation beds